Equity Research Services-Commercial Physical & Biological Research

Should You Buy iSpecimen Inc. Stock in 2026?

By CirclFi Research Team · · 10/13 models active

According to the CirclFi Deep Alpha Valuation Engine, iSpecimen Inc. (ISPC) presents a moderate quality profile with a QOC score of 5.0/10. Trading at $2.26, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.

The short answer: 7 of 10 CirclFi valuation models project upside for iSpecimen Inc. (ISPC) at $2.26 — the model consensus leans bullish, with a Quality Score of 5.0/10 and Value-Trap risk of 51/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 10 models see upside — majority bullish
  • Quality Score: 5.0/10 — Moderate — mixed signals
  • Value Trap Risk: 51/100 — Elevated — exercise caution
  • Fair Value Range: $0.14 – $13.26 (9313% spread)

Bullish Models

7 / 10

Bearish Models

3 / 10

Quality Score

5.0 /10

Moderate — mixed signals

Value Trap Risk

51 /100
Elevated

Elevated — exercise caution

Model Consensus

10 /13
Active Models

Avg. confidence: 23%

Investment Thesis

The Bull Case

Target: $13.26 (+486.6% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, 7 of 10 models identify upside from $2.26 to a composite fair value of $6.69, indicating the market hasn't fully priced in iSpecimen Inc.'s earnings power.
  • According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model targets a fair value of $13.26 (+486.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $0.14 (-93.8%)

  • According to the CirclFi Quality of Company (QOC) framework, iSpecimen Inc.'s rating of 5.0/10 indicates below-average quality, raising questions about sustainable earnings levels.
  • According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality.
  • According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.14 (-93.8%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +580.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

Peer Benchmarking

MEDP Medpace Holdings, In
10.0
IQV IQVIA Holdings, Inc.
8.7
CRL Charles River Labora
8.5
NRC NRC Health
7.3
MXCT MaxCyte, Inc.
7.3

Valuation Divergence

Spread

9313%

Fair Value Range

$0.14 – $13.26

A 9313% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Sentiment SOTP

$13.26 (+486.6%)

Most Bearish

ML-RIV

$0.14 (-93.8%)

Key Risk Factors

Value Trap Warning

VT score 51/100 — apparent discount may mask decay.

Model Disagreement

9313% spread signals high variance in projections.

Macro/Sector Risk

Services-Commercial Physical & Biological Research headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ISPC Data Page →

The Bottom Line

The balance of evidence tilts cautiously positive for iSpecimen Inc. at $2.26. 7 of 10 models support upside to $6.69, backed by a 5.0/10 quality foundation. This is a "lean into, not load up on" setup in our framework.

These are quantitative model outputs, not investment recommendations. iSpecimen Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy ISPC stock right now?

Based on CirclFi's multi-model analysis, 7 of 10 models see upside for ISPC at $2.26. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in iSpecimen Inc.?

Key risks include: an elevated Value Trap score of 51/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (9313% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Commercial Physical & Biological Research companies. Always diversify and consult a financial advisor.

How does ISPC compare to its competitors?

Among Services-Commercial Physical & Biological Research peers, ISPC holds a Quality Score of 5.0/10. Comparable companies include MEDP (QOC 10.0), IQV (QOC 8.7), CRL (QOC 8.5). The relative ranking helps investors identify whether ISPC offers better fundamental quality than alternatives in the same sector.

Is ISPC a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ISPC's Quality Score of 5.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ISPC at?

CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $0.14 to $13.26. At $2.26, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ISPC.

View ISPC Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →